Compare Mesoblast Limited (MESO) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs United Parcel Service Inc — how do they compare? Mesoblast Limited trades at $13.8 (market cap $1.81B), while United Parcel Service Inc trades at $94.5 (market cap $78.52B). The key difference: United Parcel Service Inc is far larger — about 43.4× Mesoblast Limited's market cap, and United Parcel Service Inc pays a 7.11% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mesoblast Limited for 14 Days and United Parcel Service Inc for 141 Days on average.
| MESO | UPS | |
|---|---|---|
Market Cap | $1.81B | $78.52B |
Volume | 240,620 | 5,159,366 |
Sector | Health | Industrials |
52-Week High | $20.96 | $120.00 |
52-Week Low | $13.19 | $82.87 |
Typical Hold Time | 14 Days | 141 Days |
Enterprise Value | $1.89B | $102.54B |
Dividend Yield | — | 7.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $13.94, up 2.42% on the day, amid a bearish technical signal from moving averages. The company reported a significant revenue increase to $120 million in 2026, up from $17 million in 2025, but remains unprofitable with a net loss of $58 million. Recent milestones include FDA approval for a new potency assay for Ryoncil and completion of a Phase 3 trial for chronic back pain treatment, positioning it for potential future growth.
The outlook is cautiously optimistic due to strong revenue growth and key regulatory progress, yet high cash burn and persistent losses present substantial risks. Analyst sentiment is mixed, with a 45% buy rating, but the stock faces headwinds from its negative profit margins and competitive pressures in the biotech sector.
UPS trades at $92.28, down 0.89% on the day, with a bearish technical signal despite recent earnings beats. The company maintains solid fundamentals with a P/E of 17.15 and ROE of 29.66%, though revenue has declined from $100.3B in 2022 to $88.7B in 2025. Recent developments include the launch of UPS Secure Commerce and an exclusive TikTok Shop partnership.
The outlook is mixed: analyst consensus price target of $118.67 suggests 29% upside, but technical indicators and recent downgrades highlight near-term pressure. Key risks include fuel costs, domestic volume concerns, and Amazon competition, while the 7% dividend yield provides income support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
